Post on 23-Dec-2015
Pandemic Influenza Vaccine Distribution
Selected Updates
Pandemic Influenza Vaccine: Doses Administered and Safety Training Conference
Toscha Stanley, MHSAImmunization Services Division
Centers for Disease Control and Prevention (CDC)
August 21, 2008
Vaccination periods
• Five vaccination periods (take into account both timing and supply)– Preparation period – Pre-pandemic influenza vaccination period– Manufacturing period– Early pandemic influenza vaccination period– Later pandemic influenza vaccination period
Vaccine distribution
• Initial demand expected to exceed supply– When (demand >>> supply): allocation “push” model– When (demand > supply): may transition to “pull” model
• Vaccine distribution will be monitored via CDC’s FluFinder
• States will be able to access FluFinder data for their individual state through the CDC secure data network
Direct distribution
• Manufacturer ships vaccine to states using its established distribution channels (commercial shipper or 3rd party distributor)
• May involve single or multiple manufacturers depending on the current state of domestic manufacturing capacity
Ship-to site 1(50%)
POD POD POD
Ship-to site 2(25%)
POD POD POD
Ship-to site 3(25%)
POD POD POD
State A (4% of U.S. supply)
Ship-to site 1(60%)
POD POD POD
Ship-to site 2(30%)
POD POD POD
Ship-to site 3(10%)
POD POD POD
State B (2% of U.S. supply)
Vaccine manufacturer B
3rd party distributor
Vaccine manufacturer A
Direct distribution: Pre-pandemic influenza vaccine distribution with multiple manufacturers jointly supplying states
CDC and HHS
Needle/syringe manufacturer
Ship-to site 1(50%)
POD POD POD
Ship-to site 2(25%)
POD POD POD
Ship-to site 3(25%)
POD POD POD
State A (4% of U.S. supply)
Ship-to site 1(60%)
POD POD POD
Ship-to site 2(30%)
POD POD POD
Ship-to site 3(10%)
POD POD POD
State B (2% of U.S. supply)
Vaccine manufacturer A
Direct distribution: Pandemic influenza vaccine distribution with a single manufacturer
CDC and HHS
Needle/syringe manufacturer
Operations at the state level
• State-designated ship-to sites must be capable of:– Receiving
– Storing
– Securing
– Repackaging
– Allocating to PODs
– Follow-on distribution to PODs
• Allocation, distribution, and administration within a state will be a state and local function
Ship-to sites
• Total # of Pre-pandemic vax ship-to sites = 623• Total # of Pandemic vax ship-to sites = 976
1 site 2-10 sites >10 sites
Pre-Pandemic 43 9 10Pandemic 38 8 16
• Federal ship-to sites
Single central
ship-to site
POD 1
POD 2
POD 3
State X: Single central ship-to site with direct shipment to PODs
Vaccine, adjuvant, needles and syringes
POD 4
POD 5
Single Central
ship-to site
POD 1
POD 2
POD 3Vaccine
manufacturer or distributor
POD 4
POD 5
Regional sub-ship-to
site #1
Regional Sub-ship-to
site #2
State Z: Single ship-to site with regional sub-ship-to sites within the state
Ship-to site#1
POD 1
POD 2
POD 3
POD 4
POD 5
Ship-to site#2
Ship-to site#3
State Y: Multiple ship-to sites with direct shipment to PODs
Vaccine, adjuvant, needles and syringes
The findings and conclusions in this presentation have not been formally disseminated by CDC and should not be construed to represent any agency determination or policy.
Extra Slides
Ship-to site 1(50%)
POD POD POD
Ship-to site 2(25%)
POD POD POD
Ship-to site 3(25%)
POD POD POD
State A (4% of U.S. supply)
Ship-to site 1(60%)
POD POD POD
Ship-to site 2(30%)
POD POD POD
Ship-to site 3(10%)
POD POD POD
State B (2% of U.S. supply)
Vaccine manufacturer B
Centralized distribution: Multiple manufacturers and multiple products
Vaccine manufacturer A
Central distributor
CDC and HHS
Needle/syringe manufacturer
Centralized Distribution Option